FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4316040717> ?p ?o ?g. }

• W4316040717 abstract "In 2014, the PARADIGM-HF trial (Prospective Comparison of ARNI with ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure) has shown that sacubitril/valsartan can reduce the risk of hospitalization and death from cardiovascular causes more effectively than enalapril (an ACEI) in heart failure patients with reduced ejection fraction (HFrEF). Similarly, the PARADIGM-HF trial (Comparison of Sacubitril-Valsartan vs. Enalapril on Effect on NT-proBNP in Patients Stabilized from an Acute Heart Failure Episode) came to similar conclusions and extended the PARADIGM-HF trial results in 2019. Since then, numerous new studies have provided further insight in HFrEF, sacubitril/valsartan can reduce N-terminal pro-B-type natriuretic peptide (NT-proBNP) levels, increase left ventricular ejection fraction (LVEF), reverse ventricular remodeling, and reduce other non-fatal manifestations of clinical deterioration as compared to ACEI/ARB. However, few trials have compared the effects of these drugs in patients shortly after AMI. Therefore, it is necessary to further explore the clinical efficacy and safety of sacubitril/valsartan vs. valsartan in patients with AMI.We conducted an open-label, prospective, randomized controlled trial to determine the superiority in ameliorating ventricular remodeling and preventing of heart failure in patients with AMI after percutaneous coronary intervention (PCI), 148 patients were randomly assigned (85 to sacubitril/valsartan and 63 to valsartan).LAV, LVDV, and LVSV were all decreased in the sacubitril/valsartan group when compared with before treatment, but there was no difference between the sacubitril/valsartan group and the valsartan group. In addition, compared with before treatment in the sacubitril/valsartan group, the heart global work index (GWI) and the global work efficiency (GWE) increased, while the heart global wasted work (GWW) decreased. Patients in the sacubitril/valsartan group have similar MACE and adverse side effects to those in the valsartan group.Sacubitril/valsartan has the same performance as valsartan in inhibiting ventricular remodeling and preventing heart failure after PCI in patients with AMI, and its clinical application is safe. It provides a clinical foundation for the application of sacubitril/valsartan in patients with AMI." @default.
• W4316040717 created "2023-01-14" @default.
• W4316040717 creator A5014796203 @default.
• W4316040717 creator A5018019822 @default.
• W4316040717 creator A5022728200 @default.
• W4316040717 creator A5024695372 @default.
• W4316040717 creator A5054581432 @default.
• W4316040717 creator A5072287308 @default.
• W4316040717 creator A5080123234 @default.
• W4316040717 date "2023-01-13" @default.
• W4316040717 modified "2023-09-25" @default.
• W4316040717 title "Effects of sacubitril/valsartan on cardiac reverse remodeling and cardiac resynchronization in patients with acute myocardial infarction" @default.
• W4316040717 cites W157136288 @default.
• W4316040717 cites W2029248745 @default.
• W4316040717 cites W2056792656 @default.
• W4316040717 cites W2058474974 @default.
• W4316040717 cites W2105234766 @default.
• W4316040717 cites W2143914851 @default.
• W4316040717 cites W2170674664 @default.
• W4316040717 cites W2233012668 @default.
• W4316040717 cites W2340015041 @default.
• W4316040717 cites W2592637343 @default.
• W4316040717 cites W2739918638 @default.
• W4316040717 cites W2753372655 @default.
• W4316040717 cites W2754054868 @default.
• W4316040717 cites W2771630183 @default.
• W4316040717 cites W2790459117 @default.
• W4316040717 cites W2794861476 @default.
• W4316040717 cites W2797845698 @default.
• W4316040717 cites W2899166932 @default.
• W4316040717 cites W2913819594 @default.
• W4316040717 cites W2920977137 @default.
• W4316040717 cites W2936791420 @default.
• W4316040717 cites W2940091540 @default.
• W4316040717 cites W2954586029 @default.
• W4316040717 cites W2970922997 @default.
• W4316040717 cites W3032994801 @default.
• W4316040717 cites W3045582876 @default.
• W4316040717 cites W3048778639 @default.
• W4316040717 cites W3082413032 @default.
• W4316040717 cites W3083093800 @default.
• W4316040717 cites W3100014135 @default.
• W4316040717 cites W3111137898 @default.
• W4316040717 cites W3113116966 @default.
• W4316040717 cites W3117516666 @default.
• W4316040717 cites W3124689165 @default.
• W4316040717 cites W3126159883 @default.
• W4316040717 cites W3135364842 @default.
• W4316040717 cites W3156986328 @default.
• W4316040717 cites W3162195278 @default.
• W4316040717 cites W3167258811 @default.
• W4316040717 cites W3193598686 @default.
• W4316040717 cites W3193922103 @default.
• W4316040717 cites W3196484400 @default.
• W4316040717 cites W3210435138 @default.
• W4316040717 cites W4205994763 @default.
• W4316040717 cites W4206370237 @default.
• W4316040717 cites W4207080111 @default.
• W4316040717 cites W4225761142 @default.
• W4316040717 cites W4229825080 @default.
• W4316040717 cites W4252019796 @default.
• W4316040717 doi "https://doi.org/10.3389/fcvm.2022.1059420" @default.
• W4316040717 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36712243" @default.
• W4316040717 hasPublicationYear "2023" @default.
• W4316040717 type Work @default.
• W4316040717 citedByCount "1" @default.
• W4316040717 countsByYear W43160407172023 @default.
• W4316040717 crossrefType "journal-article" @default.
• W4316040717 hasAuthorship W4316040717A5014796203 @default.
• W4316040717 hasAuthorship W4316040717A5018019822 @default.
• W4316040717 hasAuthorship W4316040717A5022728200 @default.
• W4316040717 hasAuthorship W4316040717A5024695372 @default.
• W4316040717 hasAuthorship W4316040717A5054581432 @default.
• W4316040717 hasAuthorship W4316040717A5072287308 @default.
• W4316040717 hasAuthorship W4316040717A5080123234 @default.
• W4316040717 hasBestOaLocation W43160407171 @default.
• W4316040717 hasConcept C126322002 @default.
• W4316040717 hasConcept C164705383 @default.
• W4316040717 hasConcept C27016395 @default.
• W4316040717 hasConcept C2775940317 @default.
• W4316040717 hasConcept C2775999527 @default.
• W4316040717 hasConcept C2776754050 @default.
• W4316040717 hasConcept C2777387769 @default.
• W4316040717 hasConcept C2778198053 @default.
• W4316040717 hasConcept C2779537366 @default.
• W4316040717 hasConcept C2780400711 @default.
• W4316040717 hasConcept C500558357 @default.
• W4316040717 hasConcept C71924100 @default.
• W4316040717 hasConcept C78085059 @default.
• W4316040717 hasConcept C84393581 @default.
• W4316040717 hasConceptScore W4316040717C126322002 @default.
• W4316040717 hasConceptScore W4316040717C164705383 @default.
• W4316040717 hasConceptScore W4316040717C27016395 @default.
• W4316040717 hasConceptScore W4316040717C2775940317 @default.
• W4316040717 hasConceptScore W4316040717C2775999527 @default.
• W4316040717 hasConceptScore W4316040717C2776754050 @default.
• W4316040717 hasConceptScore W4316040717C2777387769 @default.
• W4316040717 hasConceptScore W4316040717C2778198053 @default.
• W4316040717 hasConceptScore W4316040717C2779537366 @default.
• W4316040717 hasConceptScore W4316040717C2780400711 @default.

• next